Table 4 Odds of protection from (re)infection in Pfizer, Moderna and AstraZecena vaccine recipients compared to Sinopharm vaccine recipients.

From: Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh

 

Between visit 1 & 2

Between visit 2 & 3

Between visit 3 & 4

 

OR(95% CI)

P value

*MCSE

OR(95% CI)

P value

*MCSE

OR(95% CI)

P value

*MCSE

Sinopharm

Refs.

  

Refs.

  

Refs.

  

Pfizer

0.08(0.04 0.14)

 < 0.001

0.002

0.53(0.33, 1.08)

0.080

0.02

0.85(0.40, 1.81)

0.685

0.02

Moderna

0.15(0.11, 0.21)

0.001

0.004

0.52(0.35, 1.35)

0.212

0.01

0.51(0.22, 1.17)

0.112

0.004

AstraZeneca

0.13(0.09, 0.17)

0.001

0.002

0.06(0.05, 0.07)

 < 0.001

0.0007

–

–

–

  1. #Bayesian framework and MCMC methods were used to compare the effectiveness of different COVID-19 vaccines in reference to Sinopharm vaccine. The model was adjusted with age, sex, household income, occupation and BMI. #Analysis included both group I [individuals who remained uninfected with SARS-CoV-2 (tested negative by RT-PCR, did not exhibit COVID-like symptoms, negative for N-antibodies) and did not receive a 3rd dose of vaccine during the one-year study period] and group II [individuals who got infected with SARS-CoV-2 (tested positive by RT-PCR or showed COVID-like symptoms and positive for N-antibodies) and did not receive a 3rd dose during the study period]. *a smaller MCSE indicates more precise parameter estimates, while a larger MCSE suggests greater uncertainty. OR: Odds ratio; CI: Confidence interval; COVID-19: Corona virus diseases 2019; SARS-CoV-2: Severe acute respiratory coronavirus-2; RT-PCR: Reverse transcription polymerase chain reaction; MCMC: Markov chain Monte Carlo; MCSE: Monte Carlo standard error.
Back to article page